Albion Financial Group’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,368
| Closed | -$253K | – | 627 |
|
|
2024
Q4 | $253K | Buy |
1,368
+24
| +2% | +$4.43K | 0.02% | 172 |
|
|
2024
Q3 | $265K | Buy |
1,344
+1
| +0.1% | +$197 | 0.02% | 163 |
|
|
2024
Q2 | $277K | Sell |
1,343
-55
| -4% | -$11.4K | 0.02% | 168 |
|
|
2024
Q1 | $379K | Hold |
1,398
| – | – | 0.03% | 149 |
|
|
2023
Q4 | $330K | Hold |
1,398
| – | – | 0.03% | 153 |
|
|
2023
Q3 | $274K | Buy |
1,398
+120
| +9% | +$23.5K | 0.03% | 152 |
|
|
2023
Q2 | $269K | Sell |
1,278
-50
| -4% | -$10.5K | 0.02% | 160 |
|
|
2023
Q1 | $268K | Buy |
1,328
+107
| +9% | +$21.6K | 0.02% | 155 |
|
|
2022
Q4 | $266K | Sell |
1,221
-10
| -0.8% | -$2.18K | 0.03% | 154 |
|
|
2022
Q3 | $242K | Buy |
1,231
+78
| +7% | +$15.3K | 0.03% | 156 |
|
|
2022
Q2 | $247K | Sell |
1,153
-220
| -16% | -$47.1K | 0.02% | 159 |
|
|
2022
Q1 | $390K | Buy |
1,373
+7
| +0.5% | +$1.99K | 0.03% | 164 |
|
|
2021
Q4 | $515K | Sell |
1,366
-39
| -3% | -$14.7K | 0.04% | 158 |
|
|
2021
Q3 | $580K | Hold |
1,405
| – | – | 0.05% | 144 |
|
|
2021
Q2 | $520K | Buy |
+1,405
| New | +$520K | 0.05% | 147 |
|
|
2020
Q4 | $347K | Buy |
1,390
+185
| +15% | +$46.2K | 0.03% | 157 |
|
|
2020
Q3 | $273K | Buy |
+1,205
| New | +$273K | 0.03% | 188 |
|